Associate Director ImmunoGen, Inc. Marlborough, Massachusetts, United States
Antibody Drug Conjugates (ADCs), the most precise, targeted therapies, have had a promising role in cancer care over the last forty years. There have been numerous presentations and publications on ADC technology, but ADCs were only a fraction of the approvals related to overall antibody cancer treatment for years. The renaissance of the ADC field is connected to a generally better understanding of cancer cell response to treatment and technical advances. Developing new molecular entities with the desired antitumor properties via optimization of three components: antibody format, toxic drug, and more reliable linkers specifically designed to achieve more consistent conjugation and release of the drug is the primary driver of recent growth.
As the number of ADCs in development and the number of approvals for cancer treatment drastically increased, it is interesting to understand how today’s pipeline differs from that of the first golden era of ADCs in the early 2000s.
ImmunoGen, a pioneer in ADC technology, is again one of the leaders in the field. The recent approval and lunch of the commercial product, ELAHERE® exemplifies the innovation in the ADC field.
Learning Objectives:
Upon completion, participants will be able to understand how the nature of the ADC pipeline has changed over the last 20 years.
Upon completion, participants will be able to learn about new trends and approaches to targeted therapies focusing on ADC, the most precise, targeted cancer therapies.
Upon completion, participants will be able to learn about the innovative ADC platform development at ImmunoGen from recently approved ELAHERE® to the next-generation ADCs, targeting tumors with low, medium, and high receptor expression.
